glp-1 agonists weight loss drugs market Glucagon-Like Peptide (GLP)-1 Report 2026 Featuring Major Players Novo Nordisk A/S, Eli Lilly and Company, and Pfizer GLP-1 Targeted Peptide Weight Loss

The MHRA has issued alerts about falsified semaglutide products in the UK market

Monlunabant is a small molecule that blocks CB1 receptors, which is intended for oral administration

There are very few effective medications for substance use disorders, so theres a lot of excitement about whether these drugs could play a role. Why newer drugs are more powerful While early GLP-1 drugs focused on a single receptor, newer medications like tirzepatide activate more than one hormonal pathway

Bourla said that even when the drugmaker was negotiating its purchase of weight-loss drugmaker Metsera, initially announced in September 2025, Pfizer did not expect the cash-pay market for obesity drugs currently dominated by Eli Lilly and Co and Novo Nordisk to get so big, so fast

This means our blood sugar doesn't spike too quickly after meals

People interested in metabolic research, obesity science, appetite regulation, GLP-1 pathways, and next-generation weight management compounds may want to learn more about Retatrutide